Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Phase 2 Recruiting
92 enrolled
MAHOGANY
Phase 3 Recruiting
780 enrolled
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
80 enrolled
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Recruiting
500 enrolled
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Recruiting
111 enrolled
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Phase 3 Recruiting
421 enrolled
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Phase 3 Recruiting
300 enrolled
BRAZAN
Phase 2 Recruiting
60 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
33 enrolled
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Phase 2 Recruiting
108 enrolled
GLOASIS
Phase 2 Recruiting
100 enrolled
FIL_MOZART
Phase 2 Recruiting
56 enrolled
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Phase 2 Recruiting
21 enrolled
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 2 Recruiting
36 enrolled
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Phase 2 Recruiting
42 enrolled
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
Phase 4 Recruiting
18 enrolled
Mosunetuzumab for CLL MRD Clearance
Phase 1/2 Recruiting
40 enrolled
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2 Recruiting
152 enrolled
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Phase 4 Recruiting
40 enrolled
TARZAN
Phase 1 Recruiting
24 enrolled
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Phase 2 Recruiting
79 enrolled
ZEBRA
Phase 2 Recruiting
55 enrolled
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Phase 2 Recruiting
227 enrolled
ZANU-TAFA
Phase 1/2 Recruiting
27 enrolled
BOSon
Phase 2 Recruiting
40 enrolled
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Phase 2 Recruiting
230 enrolled
ARIADNE
Recruiting
705 enrolled
Pola-ZR2P in Previously Untreated DLBCL
Phase 2 Recruiting
80 enrolled
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
Phase NA Recruiting
15 enrolled
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Phase 1/2 Recruiting
51 enrolled
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
37 enrolled
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Phase 2 Recruiting
40 enrolled
ZEBRA
Phase 2 Recruiting
50 enrolled
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
106 enrolled
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Phase 2 Recruiting
240 enrolled
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Phase 2 Recruiting
52 enrolled
ZBR
Phase 2 Recruiting
42 enrolled
ZGR
Phase 2 Recruiting
39 enrolled
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Phase 3 Recruiting
100 enrolled
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2 Recruiting
30 enrolled
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2 Recruiting
23 enrolled
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Phase 2 Recruiting
41 enrolled